

Characterization of a new Post Translational Modification of Neurofibromin: atypical structural requirements for its SUMOylation

Mohammed Bergoug, Christine Mosrin-Huaman, Amandine Serrano, Fabienne Godin, Michel Doudeau, Iva Sosic, Stéphane Goffinont, Thierry Normand, Marcin Suskiewicz, Hélène Bénédetti, et al.

▶ To cite this version:

Mohammed Bergoug, Christine Mosrin-Huaman, Amandine Serrano, Fabienne Godin, Michel Doudeau, et al.. Characterization of a new Post Translational Modification of Neurofibromin: atypical structural requirements for its SUMOylation. 2024 Global NF Conference, Jun 2024, Brussels, Belgium. hal-03679991

HAL Id: hal-03679991 https://hal.science/hal-03679991v1

Submitted on 12 Nov 2024 $\,$

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Characterization of a new Post Translational Modification of Neurofibromin:





atypical structural requirements for its SUMOylation


M. Bergoug, C. Mosrin, A. Serrano, F. Godin, M. Doudeau, I. Sosic, S. Goffinont, T. Normand, M. Suskiewicz, H. Benedetti, and <u>Béatrice Vallée</u>

Centre de Biophysique Moléculaire (CBM), CNRS UPR4301, Orléans

Nf1 and SUMO

• Neurofibromin, Nf1, the protein encoded by *NF1* gene

• *NF1* is a tumor-suppressor gene which encodes Neurofibromin, Nf1. • Nf1 is a giant multidomain protein (isoform 1/2 2818/2839 aa). • Initially characterized by its Ras-GAP activity, Nf1 is also involved in numerous other pathways due to its numerous partners.




Nf1 post-translational modifications

• Nf1 colocalizes with PML nuclear bodies

(Godin *et al.*, 2012) PML: ProMyelocytic Leukemia

PML Nuclear Bodies


and SUMO





• SUMO, a post-translational modification

• Reversible Post Translational Modification (PTM) • Rare event: steady-state, SUMOylation is usually less than 5% • Multiple functional roles : protein/protein interaction, protein stability, protein subcellular localization • Several neurodegenerative diseases rely on SUMO modification • SUMO-based therapies are currently developed



Phosphorylation: C-Terminal Domain has been shown to be phosphorylated by PKA (interaction with 14-3-3) and PKCε (nuclear entry). **Display Ubiquitination**: Nf1 is negatively regulated by different ubiquitin ligases which induce its proteasomal degradation.


(red, PML-NBs) which are hot spots of SUMOylation. Show Nf1 and PML proteins belong to the same multiprotein complex

• SUMOylation occurs on Lys residues belonging to a consensus sequence (ΨKxE/D, Ψ being an hydrophobic residue, x any residue) or via the help of the SIM domain of the substrate which allows the recruitment of the E2, Ubc9.

The SecPH domain of Nf1 is SUMOylated on its Lys1731 and 1634


SecPH domain of NF1

• The SecPH domain contains the highest number of SUMOylation consensus sites, 5 sites are predicted to be SUMOylated




• As evidenced by the recently resolved CryoEM structures of Nf1 dimer, it is exposed at the surface of the dimer and it is proned with its adjacent GRD domain, to a structural rearrangement, • Pleckstrin Homology (PH) domains are enriched in SUMOylation substrates,

• SecPH might play an important role in Nf1 function as it could allosterically affect GRD Ras-GAP function and as it interacts with many partners (lipids, VCP, LIMK2, 5HT6, caveolin).




SecPH is characterized by 4 bands of monoSUMOylation

 SecPH SUMOylated Lys determination Each Lysine has been substituted by Arginine either individually (left), in combination (right) and analysed by PD (poll-down) affinity on cobalt beads



Solution Band 2 disappears in K1731R mutant **Band 3 disappears in K1634R mutant** K1731 and 1634 localization 3-protrusion ♦ K1731 and 1634 are

surface exposed



• K1731 pathogenicity


In the gnomAD database a c.5192A>G

Molecular mechanisms of SUMOylation


K1731 SUMOylation does not depend on ΨKxE/D consensus site



♦ K1731 remains modified independently of the inverted SUMO consensus sequence ΨKxE/D surrounding it



• K1731 SUMOylation does not depend on its SIM domain




SUMO SIM of SecPH SecPH

> SecPH SIM domain is not accessible to SUMO binding as it is surrounded by **β-strands**

Proposed model for SecPH SUMOylation on K1731


• The loop 1723-1729 of SecPH contributes to the recognition of K1731 for SUMOylation

 Residues R1748 and K1750 of the βprotusion are essential for SecPH



SUMOvlation on K1731 SUMO Ubc9 Nf1 SecPH

SecPH SUMOylation on its K1731 relies on a tertiary structural environment around this amino acid, which has never been described in the literature so far.



^t♦ K1731 SUMOylation of SecPH is mediated by two surface-exposed structural elements the PH domain, the loop 1723-1729 and the β -protrusion, which form a complex composite "structural motif" for recruiting Ubc9 and positioning it on K1731. ♥ This mechanism is totally atypical.

 \bigcirc Link to NF1 disease: some pathogenic patients harbour single mutation in this loop or in the β -protusion.